
Humana, Boston Scientific, Hims & Hers Health, Gilead Sciences, and HCA Healthcare are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, including pharmaceuticals, biotechnology, medical devices, hospitals, diagnostics, and health insurance. Investors may buy these stocks to gain exposure to healthcare-sector growth, though their performance can be affected by clinical-trial results, regulations, drug approvals, and changes in healthcare demand. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Humana (HUM)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Boston Scientific (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read Our Latest Research Report on BSX
Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
Read Our Latest Research Report on HIMS
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read Our Latest Research Report on GILD
HCA Healthcare (HCA)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Read Our Latest Research Report on HCA
Featured Stories
- MarketBeat’s Top Five Stocks to Own in August 2026
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
